Overview

Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A study to explore the safety and efficacy of treatment with BDB-001 Injection in adults with moderate to severe hidradenitis suppurativa (HS).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Collaborator:
Beijing Defengrui Biotechnology Co. Ltd